文献速递肾移植肾小球疾病血液净化与透析

肾移植在单克隆免疫球蛋白沉积病中的作用

The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease.
PubMed 文献 · Kidney Int Rep · 2020-03-09

该回顾性分析纳入23例单克隆免疫球蛋白沉积病(MIDD)患者,其中6例接受肾移植。诊断后1、5、10年总生存率分别为95%、78%、65%,肾存活率分别为77%、48%、29%。接受肾移植者中位总生存期显著优于维持透析者(19.8年 vs 8.3年,P=0.016)。

要点

  • MIDD患者诊断后10年肾存活率仅29%,约半数进展至终末期肾病。
  • 肾移植者中位总生存期19.8年,显著优于透析者的8.3年。
  • 肾脏应答仅见于5例(22%),均在获得血液学完全缓解后。

核心结论

  • 随着MIDD治疗改善,更多患者获得持续血液学缓解,肾移植后患者及移植物存活更久。

研究设计与样本

  • 回顾性分析23例MIDD患者的长期肾脏结局,其中6例接受肾移植。

主要发现

  • 诊断后1、5、10年总生存率分别为95%、78%、65%。
  • 12例(约半数)进展至终末期肾病,诊断至ESRD中位时间3.4年。
  • 诊断后1、5、10年肾存活率分别为77%、48%、29%。
  • 肾脏应答仅见于5例(22%),均在血液学完全缓解后。
  • 肾移植者中位总生存期19.8年,透析者8.3年(P=0.016)。

临床怎么用

  • MIDD患者进展至终末期肾病风险高,肾移植可能带来显著生存获益。
  • 肾移植前应争取血液学完全缓解,以降低疾病复发导致移植物丢失风险。

局限性

  • 回顾性分析,样本量小(共23例,肾移植仅6例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Monoclonal Ig deposition disease (MIDD) frequently leads to kidney failure, and a large proportion of these patients would greatly benefit from kidney transplantation. However, data on kidney transplantation outcomes in MIDD are limited. METHODS: This was a retrospective analysis of long-term renal outcomes of 23 patients with MIDD, including 6 patients who underwent kidney transplantation. RESULTS: The 1-, 5-, and 10-year overall survival (OS) from diagnosis were 95%, 78%, and 65%, respectively. Approximately half of the patients (n = 12) progressed to end-stage renal disease (ESRD) with a median time from diagnosis to ESRD of 3.4 years. The 1-, 5-, and 10-year renal survival from diagnosis were 77%, 48%, and 29% respectively. Renal response was observed only in 5 patients (22%), all of them after achieving hematologic complete response. Median OS from diagnosis was significantly better for those who underwent kidney transplantation versus those who remained on dialysis (19.8 years vs. 8.3 years, P = 0.016). Among patients who underwent kidney transplantation, the shortest survival from MIDD diagnosis was 13.7 years and the longest was 27.8 years. Of the 3 patients with kidney transplants who died, the time from the first kidney transplantation to death was 7.4, 18.8, and 20.4 years. Graft loss due to disease recurrence occurred at 4 months and 3.8 years after kidney transplantation in 2 patients who either were not treated or did not respond to treatment. CONCLUSION: As treatments for MIDD have dramatically improved, more patients are achieving sustained hematologic responses with longer patient and graft survival after kidney transplantation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Angel-Korman A, Stern L, Angel Y, et al. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020. PMID: 32274452. doi:10.1016/j.ekir.2020.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。